• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Lantheus Holdings Inc.

    5/30/25 4:30:17 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $LNTH alert in real time by email
    SD 1 d26613dsd.htm SD SD
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM SD

     

     

    Specialized Disclosure Report

     

     

    LANTHEUS HOLDINGS, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-36569   35-2318913

    (State or other jurisdiction

    of incorporation or organization)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    201 Burlington Road, South Building Bedford, MA   01730
    (Address of principal executive offices)   (Zip Code)

    Daniel M. Niedzwiecki

    Chief Administrative Officer, General Counsel

    and Corporate Secretary

    (978) 671-8001

    (Name and telephone number, including area code, of the person to contact in connection with this report.)

     

     

    Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this Form applies:

     

    ☒

    Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2024.

     

    ☐

    Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended _______.

     

     
     


    Section 1 - Conflict Minerals Disclosure

     

    Item 1.01

    Conflict Minerals Disclosure and Report

    Conflict Minerals Disclosure

    A copy of Lantheus Holdings, Inc.’s Conflict Minerals Report for the reporting period January 1, 2024 through December 31, 2024 is provided as Exhibit 1.01 under Item 3.01 of this Form SD (the “Conflict Minerals Report”) and is also publicly available at www.lantheus.com.

    The content of any website referred to in this Form SD or the Conflict Mineral Report is included for general information only and is not incorporated by reference in this Form SD.

     

    Item 1.02

    Exhibit

    See Item 1.01.

    Section 2 – Resource Extraction Issuer Disclosure

     

    Item 2.01

    Resource Extraction Issuer Disclosure and Report

    Not applicable.

    Section 3 – Exhibits

     

    Item 3.01

    Exhibits

    Exhibit 1.01 – Conflict Minerals Report for the reporting period January 1, 2024 through December 31, 2024.

     

    1


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.

     

    LANTHEUS HOLDINGS, INC.
    (Registrant)

     

    /s/ Daniel M. Niedzwiecki    May 30, 2025

    By: Daniel M. Niedzwiecki, Chief Administrative

    Officer, General Counsel and Corporate Secretary

       (Date)

     

    2


    EXHIBIT INDEX

     

    Exhibit
    Number
      

    Description

    1.01    Conflict Minerals Report for the reporting period January 1, 2024 through December 31, 2024.

     

    3

    Get the next $LNTH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LNTH

    DatePrice TargetRatingAnalyst
    8/12/2025$63.00Buy → Hold
    Truist
    12/18/2024$143.00Buy
    Goldman
    9/3/2024$175.00Buy
    Redburn Atlantic
    7/10/2024$100.00 → $130.00Mkt Outperform
    JMP Securities
    12/18/2023Outperform → Mkt Perform
    William Blair
    12/4/2023$100.00Outperform
    TD Cowen
    9/29/2023Outperform
    William Blair
    3/8/2023$120.00Mkt Outperform
    JMP Securities
    More analyst ratings

    $LNTH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Dinkelborg Ludger claimed no ownership of stock in the company (SEC Form 3)

    3 - Lantheus Holdings, Inc. (0001521036) (Issuer)

    8/18/25 5:22:18 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    New insider Patel Rajiv A claimed ownership of 6,883,227 shares (SEC Form 3)

    3 - Lantheus Holdings, Inc. (0001521036) (Issuer)

    8/18/25 4:03:44 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    New insider Farallon Partners L L C/Ca claimed ownership of 6,883,227 shares (SEC Form 3)

    3 - Lantheus Holdings, Inc. (0001521036) (Issuer)

    8/18/25 4:03:23 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $LNTH
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Lantheus Holdings Inc.

    SCHEDULE 13G/A - Lantheus Holdings, Inc. (0001521036) (Subject)

    8/14/25 11:17:17 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 144 filed by Lantheus Holdings Inc.

    144 - Lantheus Holdings, Inc. (0001521036) (Subject)

    8/13/25 12:48:42 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 8-K filed by Lantheus Holdings Inc.

    8-K - Lantheus Holdings, Inc. (0001521036) (Filer)

    8/11/25 5:02:48 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $LNTH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lantheus Holdings downgraded by Truist with a new price target

    Truist downgraded Lantheus Holdings from Buy to Hold and set a new price target of $63.00

    8/12/25 7:56:11 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Goldman initiated coverage on Lantheus Holdings with a new price target

    Goldman initiated coverage of Lantheus Holdings with a rating of Buy and set a new price target of $143.00

    12/18/24 7:37:47 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Redburn Atlantic initiated coverage on Lantheus Holdings with a new price target

    Redburn Atlantic initiated coverage of Lantheus Holdings with a rating of Buy and set a new price target of $175.00

    9/3/24 8:07:35 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $LNTH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lantheus Reports Second Quarter 2025 Financial Results and Provides Business Update

    Recorded second quarter 2025 worldwide revenue of $378.0 million, GAAP fully diluted earnings per share of $1.12, adjusted fully diluted earnings per share of $1.57 and free cash flow of $79.1 millionAnnounced FDA acceptance of NDA for new formulation for piflufolastat F 18 PSMA PET imaging agent with a PDUFA date of March 6, 2026Closed acquisition of Life Molecular Imaging in July, immediately expanding near- and long-term growth profile and commercial portfolio with Neuraceq® (florbetaben F 18 injection), a globally approved beta-amyloid targeted radiodiagnostic for Alzheimer's disease; FDA label expansion for Neuraceq in JuneBoard of Directors authorized a program to repurchase up to $400

    8/6/25 7:00:00 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Lantheus Announces FDA Acceptance of NDA for New Formulation for Market-Leading PSMA PET Imaging Agent

    Designed to expand PSMA PET imaging access for patients by increasing batch size by ~50% and enhancing supply resiliencePDUFA date set for March 6, 2026 BEDFORD, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that the Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for a new formulation of its F 18 PSMA imaging agent filed by its affiliate, Aphelion. The FDA has set an action date goal of March 6, 2026 under the Prescription Drug User Fee Act (PDUFA

    8/6/25 6:45:00 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Lantheus to Host Second Quarter 2025 Earnings Conference Call and Webcast on August 6, 2025, at 8:00 a.m. Eastern Time

    BEDFORD, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the "Company") (NASDAQ:LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, August 6, 2025, to discuss its financial results and provide a business update for the second quarter of 2025. To access the conference call or webcast, participants should register online at https://investor.lantheus.com/news-events/calendar-of-events. To avoid delays, we encourage participants to register fifteen minutes ahead of the scheduled start time. A replay will be available approximately two hours after completion of the webcast and will be archived on the same web page for at least

    7/23/25 8:00:00 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $LNTH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Lantheus Alpha Therapy, Llc bought $57,409,487 worth of shares (60,431,039 units at $0.95) (SEC Form 4)

    4 - Lantheus Holdings, Inc. (0001521036) (Reporting)

    3/8/24 11:24:53 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $LNTH
    Leadership Updates

    Live Leadership Updates

    View All

    Lantheus Completes Acquisition of Life Molecular Imaging and Appoints Dr. Ludger Dinkelborg as Head of R&D

    BEDFORD, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ:LNTH), today announced the successful completion of its previously disclosed acquisition of Life Molecular Imaging Ltd. ("Life Molecular"), a subsidiary of Life Healthcare Group Holdings Ltd ("Life Healthcare"). As part of the acquisition, Ludger Dinkelborg, PhD, formerly CEO and Managing Director of Life Molecular Imaging, has been appointed Head of Research and Development at Lantheus effective August 1, 2025. "We are thrilled to welcome Dr. Dinkelborg and the entire Life Molecular team to Lantheus," said Brian Markison, CEO of Lantheus. "Ludger's proven leadership, scientific

    7/22/25 7:00:00 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    PharmaLogic Announces Appointment of Etienne Montagut as President and Chief Executive Officer

    BOCA RATON, Fla., June 2, 2025 /PRNewswire/ -- PharmaLogic Holdings Corp. ("PharmaLogic" or "the Company"), a leading contract development and manufacturing organization (CDMO) specialized in radiopharmaceuticals, today announces the Company has appointed Etienne Montagut, currently serving as President, to the position of President and Chief Executive Officer, effective as of 1 June 2025. Mr. Montagut brings over 25 years of senior leadership experience in the pharmaceutical sector, with a solid track record of driving growth and executing strategic transformation across glob

    6/2/25 8:00:00 AM ET
    $GEHC
    $LNTH
    Medical Electronics
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    Lantheus Appoints Phuong Khanh (P.K.) Morrow, M.D., as New Board Member

    BEDFORD, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Phuong Khanh (P.K.) Morrow, M.D. to Lantheus' Board of Directors ("Board"), effective February 1, 2025. Dr. Morrow is an experienced pharmaceutical executive and physician-scientist with deep expertise leading end-to-end clinical development in the field of oncology. As an independent director, Dr. Morrow will serve as a member of the Board's Science and Technology Committee, where her proven track record i

    1/30/25 8:30:00 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $LNTH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Lantheus Holdings Inc.

    SC 13G - Lantheus Holdings, Inc. (0001521036) (Subject)

    11/14/24 8:21:14 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13G/A filed by Lantheus Holdings Inc.

    SC 13G/A - Lantheus Holdings, Inc. (0001521036) (Subject)

    11/14/24 3:29:28 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G filed by Lantheus Holdings Inc.

    SC 13G - Lantheus Holdings, Inc. (0001521036) (Subject)

    2/14/24 1:18:20 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $LNTH
    Financials

    Live finance-specific insights

    View All

    Lantheus Reports Second Quarter 2025 Financial Results and Provides Business Update

    Recorded second quarter 2025 worldwide revenue of $378.0 million, GAAP fully diluted earnings per share of $1.12, adjusted fully diluted earnings per share of $1.57 and free cash flow of $79.1 millionAnnounced FDA acceptance of NDA for new formulation for piflufolastat F 18 PSMA PET imaging agent with a PDUFA date of March 6, 2026Closed acquisition of Life Molecular Imaging in July, immediately expanding near- and long-term growth profile and commercial portfolio with Neuraceq® (florbetaben F 18 injection), a globally approved beta-amyloid targeted radiodiagnostic for Alzheimer's disease; FDA label expansion for Neuraceq in JuneBoard of Directors authorized a program to repurchase up to $400

    8/6/25 7:00:00 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Lantheus to Host Second Quarter 2025 Earnings Conference Call and Webcast on August 6, 2025, at 8:00 a.m. Eastern Time

    BEDFORD, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the "Company") (NASDAQ:LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, August 6, 2025, to discuss its financial results and provide a business update for the second quarter of 2025. To access the conference call or webcast, participants should register online at https://investor.lantheus.com/news-events/calendar-of-events. To avoid delays, we encourage participants to register fifteen minutes ahead of the scheduled start time. A replay will be available approximately two hours after completion of the webcast and will be archived on the same web page for at least

    7/23/25 8:00:00 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Lantheus Reports First Quarter 2025 Financial Results and Provides Business Update

    Worldwide revenue of $372.8 million in the first quarter 2025GAAP fully diluted earnings per share of $1.02, compared to $1.87 in the first quarter of 2024; adjusted fully diluted earnings per share of $1.53, compared to $1.69 in the first quarter of 2024Free cash flow totaled $98.8 million for the first quarter 2025Closed acquisition of Evergreen Theragnostics early in the second quarter; expect to close on acquisition of Life Molecular Imaging in the coming weeks; and yesterday announced planned divestiture of SPECT businessRecently announced positive data for two MK-6240 pivotal studies; plan to file NDA in the third quarter of 2025Provided updated interim corporate guidance for full year

    5/7/25 7:00:00 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care